 |
InterPro: IPR000980 SH2 motif
Protein matches
|
UniProtKB Matches: 2970 proteins |
|
Accession
|
IPR000980 SH2 |
Type
|
Domain |
Signatures
|
|
InterPro Relationships
|
|
Found in
|
IPR001217 STAT transcription factor, core
IPR001720 PI3 kinase, P85 regulatory subunit
IPR009127 Tyrosine-protein kinase, JAK, conserved region
IPR009128 Tyrosine-protein kinase, JAK1
IPR009129 Tyrosine-protein kinase, JAK2, conserved region
IPR009130 Tyrosine-protein kinase, JAK3
IPR009131 Tyrosine-protein kinase, non-receptor, TYK2
IPR012152 Protein-tyrosine phosphatase, non-receptor type-6, -11
IPR012234 Tyrosine-protein kinase, non-receptor SYK/ZAP-70
IPR015773 Tyrosine-protein kinase, non-receptor MATK
IPR015774 Tyrosine-protein kinase, non-receptor PTK6
IPR015778 Tyrosine-protein kinase, non-receptor Csk
IPR016045 Tyrosine-protein kinase, non-receptor, TYK2, N-terminal
IPR016250 Tyrosine-protein kinase, non-receptor Fes, subgroup
IPR016251 Tyrosine-protein kinase, non-receptor Jak/Tyk2
IPR016279 Phosphatidylinositol-4, 5-bisphosphate phosphodiesterase gamma
IPR017072 Transcription elongation factor Spt6
IPR017289 SH2 protein 1A
IPR017304 Cytoplasmic, NCK
IPR017356 N-chimaerin
IPR020685 Tyrosine-protein kinase
IPR020686 Tyrosine-protein kinase, non-receptor ZAP-70
IPR020693 Tyrosine-protein kinase, non-receptor Jak2
IPR020697 Tyrosine-protein kinase, non-receptor ITK/TSK
IPR020698 Tyrosine-protein kinase, non-receptor Btk29A
IPR020699 Tyrosine-protein kinase, non-receptor Srms
IPR020700 Tyrosine-protein kinase, non-receptor Abl
IPR020701 Tyrosine-protein kinase, non-receptor Src-1, nematode
IPR020702 Tyrosine-protein kinase, non-receptor FRK
IPR020703 Tyrosine-protein kinase, non-receptor Src64B
IPR020743 Tyrosine-protein kinase, non-receptor YES
IPR020744 Tyrosine-protein kinase, non-receptor Src
IPR020745 Tyrosine-protein kinase, non-receptor Fyn
IPR020746 Tyrosine-protein kinase, non-receptor Fgr
IPR020747 Tyrosine-protein kinase, non-receptor Lyn
IPR020748 Tyrosine-protein kinase, non-receptor Hck
IPR020749 Tyrosine-protein kinase, non-receptor Lck
IPR020750 Tyrosine-protein kinase, non-receptor Blk
IPR020753 Tyrosine-protein kinase, non-receptor Btk
IPR020755 Tyrosine-protein kinase, non-receptor Txk/Tec
IPR020757 Tyrosine-protein kinase, non-receptor SYK
IPR020764 Tyrosine-protein kinase, non-receptor Fes
IPR020771 Tyrosine-protein kinase, non-receptor Shark
IPR020775 Tyrosine-protein kinase, non-receptor Jak3
IPR020776 Tyrosine-protein kinase, non-receptor Jak1
|
GO Term annotation
|
|
Function
|
GO:0005515 protein binding
|
|
InterPro annotation
|
|
Entry Details in BioMart
|
Abstract
|
The Src homology 2 (SH2) domain is a protein domain of about 100 amino-acid residues first identified as a conserved sequence region between the oncoproteins Src and Fps [1]. Similar sequences were later found in many other intracellular signal-transducing proteins [2]. SH2 domains function as regulatory modules of intracellular signalling cascades by interacting with high affinity to
phosphotyrosine-containing target peptides in a sequence-specific, SH2 domains recognise between 3-6 residues C-terminal to the phosphorylated tyrosine in a fashion that differs from one SH2 domain to another, and strictly phosphorylation-dependent manner [3, 4, 5, 6]. They are found in a wide variety of protein contexts e.g., in association with catalytic domains of phospholipase Cy (PLCy) and the non-receptor protein
tyrosine kinases; within structural proteins such as fodrin and tensin; and in a group of small adaptor molecules, i.e Crk and Nck. The domains are frequently found as repeats in a single protein sequence and will then often bind both mono- and di-phosphorylated substrates.
The structure of the SH2 domain belongs to the alpha+beta class, its overall shape forming a compact flattened hemisphere. The core structural elements comprise a central hydrophobic anti-parallel beta-sheet, flanked by 2 short alpha-helices. The loop between strands 2 and 3 provides many of the binding interactions with the phosphate group of its phosphopeptide ligand, and is hence designated the phosphate binding loop, the phosphorylated ligand binds perpendicular to the beta-sheet and typically interacts with the phosphate binding loop and a hydrophobic binding pocket that interacts with a pY+3 side chain. The N- and C-termini of the domain are close together in space and on the opposite face from the phosphopeptide binding surface and it has been speculated that this has facilitated their integration into surface-exposed regions of host proteins [7].
|
Structural links
|
|
Database links
|
|
Interactions
|
This domain has been experimentally proven to be involved in Protein:Protein interactions. Representative
data is shown with the following
example proteins:
|
Additional Reading
|
|
Deak HL, Newcomb JR, Nunes JJ, Boucher C, Cheng AC, DiMauro EF, Epstein LF, Gallant P, Hodous BL, Huang X, Lee JH, Patel VF, Schneider S, Turci SM, Zhu X.
N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Bioorg. Med. Chem. Lett. 18 2008 1172-6
[PubMed: 18083554]
http://dx.doi.org/10.1016/j.bmcl.2007.11.123
|
|
Jacobs MD, Caron PR, Hare BJ.
Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
Proteins 70 2008 1451-60
[PubMed: 17910071]
http://dx.doi.org/10.1002/prot.21633
|
|
Ng C, Jackson RA, Buschdorf JP, Sun Q, Guy GR, Sivaraman J.
Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates.
EMBO J. 27 2008 804-16
[PubMed: 18273061]
http://dx.doi.org/10.1038/emboj.2008.18
|
|
Houlard M, Romero-Portillo F, Germani A, Depaux A, Regnier-Ricard F, Gisselbrecht S, Varin-Blank N.
Characterization of VIK-1: a new Vav-interacting Kruppel-like protein.
Oncogene 24 2005 28-38
[PubMed: 15558030]
http://dx.doi.org/10.1038/sj.onc.1208043
|
|
Overduin M, Rios CB, Mayer BJ, Baltimore D, Cowburn D.
Three-dimensional solution structure of the src homology 2 domain of c-abl.
Cell 70 1992 697-704
[PubMed: 1505033]
http://dx.doi.org/10.1016/0092-8674(92)90437-H
|
|
Taylor JD, Ababou A, Fawaz RR, Hobbs CJ, Williams MA, Ladbury JE.
Structure, dynamics, and binding thermodynamics of the v-Src SH2 domain: implications for drug design.
Proteins 73 2008 929-40
[PubMed: 18536014]
http://dx.doi.org/10.1002/prot.22119
|
|
Jones N, Blasutig IM, Eremina V, Ruston JM, Bladt F, Li H, Huang H, Larose L, Li SS, Takano T, Quaggin SE, Pawson T.
Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes.
Nature 440 2006 818-23
[PubMed: 16525419]
http://dx.doi.org/10.1038/nature04662
|
|
Petsko GA.
Signal transduction. Fishing in Src-infested waters.
Nature 358 1992 625-6
[PubMed: 1379695]
http://dx.doi.org/10.1038/358625a0
|
|
Montoye T, Lemmens I, Catteeuw D, Eyckerman S, Tavernier J.
A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach.
Blood 105 2005 4264-71
[PubMed: 15644415]
http://dx.doi.org/10.1182/blood-2004-07-2733
|
|
Waksman G, Kominos D, Robertson SC, Pant N, Baltimore D, Birge RB, Cowburn D, Hanafusa H, Mayer BJ, Overduin M.
Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides.
Nature 358 1992 646-53
[PubMed: 1379696]
http://dx.doi.org/10.1038/358646a0
|
|
Lee MF, Beauchamp RL, Beyer KS, Gusella JF, Ramesh V.
Magicin associates with the Src-family kinases and is phosphorylated upon CD3 stimulation.
Biochem. Biophys. Res. Commun. 348 2006 826-31
[PubMed: 16899217]
http://dx.doi.org/10.1016/j.bbrc.2006.07.126
|
|
Ozawa T, Tsuji E, Ozawa M, Handa C, Mukaiyama H, Nishimura T, Kobayashi S, Okazaki K.
The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase.
Bioorg. Med. Chem. 16 2008 10311-8
[PubMed: 18977146]
http://dx.doi.org/10.1016/j.bmc.2008.10.041
|
|
Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R.
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Oncogene 26 2007 6989-96
[PubMed: 17486070]
http://dx.doi.org/10.1038/sj.onc.1210500
|
|